Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative

symbol logo$PTCT Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.62 down -410.00% YoY • Reported revenue of $357.81M up 69.57% YoY • PTC Therapeutics increased full-year 2026 expected total revenue to $1.29 to $1.32B and raised product revenue guidance to $960 to $990M; GAAP expense guidance remains $775 to $815M.

Price since post

Full Details

Advertisement|Remove ads.